Wall Street Zen Upgrades Lantheus (NASDAQ:LNTH) to Strong-Buy

Lantheus (NASDAQ:LNTH) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “strong-buy” rating in a research note issued on Saturday.

LNTH has been the topic of several other research reports. William Blair upgraded shares of Lantheus from a “market perform” rating to an “outperform” rating in a research note on Thursday, February 26th. Mizuho lifted their target price on Lantheus from $72.00 to $85.00 and gave the company an “outperform” rating in a research note on Friday, February 27th. Truist Financial upped their target price on Lantheus from $82.00 to $89.00 and gave the company a “buy” rating in a report on Friday, February 27th. Citizens Jmp increased their price target on Lantheus from $73.00 to $78.00 and gave the stock a “market outperform” rating in a research report on Tuesday, February 24th. Finally, JonesTrading downgraded Lantheus from a “buy” rating to a “hold” rating in a report on Friday, February 27th. Seven investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $82.17.

Lantheus Stock Performance

Lantheus stock opened at $72.56 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.70 and a quick ratio of 2.51. Lantheus has a 12 month low of $47.25 and a 12 month high of $111.29. The company has a fifty day moving average price of $69.11 and a two-hundred day moving average price of $60.98. The company has a market cap of $4.69 billion, a PE ratio of 21.53 and a beta of -0.11.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share for the quarter, topping analysts’ consensus estimates of $1.17 by $0.50. Lantheus had a net margin of 15.15% and a return on equity of 30.77%. The company had revenue of $406.79 million for the quarter, compared to analysts’ expectations of $367.03 million. During the same period in the prior year, the company earned $1.59 earnings per share. The firm’s revenue was up 4.0% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Research analysts expect that Lantheus will post 6.01 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of LNTH. Stanley Laman Group Ltd. boosted its position in shares of Lantheus by 38.7% during the third quarter. Stanley Laman Group Ltd. now owns 79,686 shares of the medical equipment provider’s stock worth $4,087,000 after buying an additional 22,229 shares during the period. Quantbot Technologies LP acquired a new stake in Lantheus in the 3rd quarter valued at approximately $1,847,000. American Assets Inc. bought a new stake in Lantheus during the 3rd quarter valued at $872,000. Campbell & CO Investment Adviser LLC bought a new stake in Lantheus during the 3rd quarter valued at $2,184,000. Finally, Assetmark Inc. boosted its position in Lantheus by 20.1% during the 3rd quarter. Assetmark Inc. now owns 118,503 shares of the medical equipment provider’s stock worth $6,078,000 after acquiring an additional 19,844 shares during the period. Institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.